Last reviewed · How we verify

Peripheral arterial embolism — Treatment Landscape & Competitive Intelligence

Peripheral arterial embolism (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Peripheral arterial embolism, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Heparin Sodium In Plastic Container HEPARIN Merck & Co. Anti-coagulant Antithrombin-III 1939-01-01
Heparin Sodium In Plastic Container Heparin Sodium Fresenius Kabi Anticoagulant Antithrombin III, Coagulation Factors Xa and IIa 1939-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Fresenius Kabi · 1 drug in Peripheral arterial embolism
  2. Merck & Co. · 1 drug in Peripheral arterial embolism

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Peripheral arterial embolism:

Cite this brief

Drug Landscape (2026). Peripheral arterial embolism — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/peripheral-arterial-embolism. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing